|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.94 USD | +3.94% |
|
+11.94% | -44.01% |
| 05-08 | Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating | MT |
| 05-08 | Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q1 Revenue $11.7M | MT |
EyePoint Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 46.02 million compared to USD 41.4 million a year ago. Net loss was USD 70.8 million compared to USD 102.25 million a year ago.
Basic loss per share from continuing operations was USD 1.82 compared to USD 2.74 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -44.01% | 674M | |
| +31.37% | 595B | |
| -2.60% | 367B | |
| +20.83% | 334B | |
| +5.69% | 289B | |
| +14.83% | 239B | |
| +9.93% | 211B | |
| -6.95% | 203B | |
| +10.77% | 171B | |
| +0.10% | 163B |
EYEPOINT PHARMACEUTICALS, INC. 